A long-term study on effectiveness of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients
Objective: To present the design of and baseline patient characteristics from an ongoing global study assessing the long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG, carbidopa-levodopa…An Unusual Cause of Rhabdomyolysis in Parkinson’s disease
Objective: To describe an unusual cause of rhabdomyolysis in patient with advanced Parkinson’s disease (PD) treated with levodopa. Background: Rhabdomyolysis is a serious and life-threatening…Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.
Objective: To define variation in L-dopa response in recent onset PD. Background: L-Dopa responsiveness is a defining feature of Parkinson’s disease (PD), but the degree…Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study
Objective: Evaluate the efficacy and safety of IPX203 vs. immediate-release (IR) carbidopa-levodopa (CD-LD) and vs. extended-release (ER) CD-LD (IPX066, RYTARY®) in patients with advanced Parkinson’s…Preliminary results of a cross-linguistic comparison on dysarthria in Parkinson’s disease
Objective: To evaluate the effects of language, disease duration, and medication on acoustic and prosodic parameters in the speech of Parkinson's disease (PD) patients. Background:…MEK inhibitors have antidyskinetic effects in hemiParkinsonian rats that are associated with critical neurochemical alterations in the striatum
Objective: To examine the effects of MEK inhibitors PD98059 and U0126 on L-DOPA-induced dyskinesia and the induced molecular changes. Background: L-DOPA-induced dyskinesia (LID) represents one…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…Experience with utilization of rytary in the clinical setting
Objective: To explore the utilization and tolerability of Rytary in the clinical setting. Background: Rytary is a novel extended-release carbidopa-levodopa (CD-LD) formulation that was approved…The effect of levodopa-carbidopa intestinal gel on activities of daily living: Results from the observational MONOTREAT study in advanced Parkinson’s disease patients
Objective: To assess the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on activities of daily…Comorbid conditions associated with Parkinson´s disease: A longitudinal study
Objective: (1)To study what comorbid conditions were present at baseline and 3 years later in a cohort of Spanish PD patients and (2) to analyze…
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 62
- Next Page »